NEWS
PRESS CENTER
2020
2021-08-25
- In February, we completed Series B financing
- In February, we acquired global license of LAE005 from Novartis
- In August, we received IND approval for pivotal Phase II MRCT study of LAE002 plus paclitaxel versus paclitaxel in patients with PROC from NMPA in China
- In December, we received IND approval for Phase I/II clinical trial of LAE002 combined with LAE005 and nab-paclitaxel for TNBC from NMPA in China
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy
